Cytek Biosciences, Inc. CTKB Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$18.87M-65.5% | -$44.08M— | -$5.48M-682% | -$5.58M+46.5% | -$11.4M-84.8% | ||
| $1.87M-0.5% | $1.9M+2.3% | $1.92M+3.6% | $1.89M+4.5% | $1.88M+10.4% | ||
| $4.86M-26.7% | $5.53M-21.1% | $5.64M-20.1% | $6.79M-5.1% | $6.63M+17.6% | ||
| -$183K+45.5% | $38.58M+1,437% | -$2.63M— | -$2.06M— | -$336K— | ||
| -$55K+45.5% | -$60K-1,900% | -$102K— | -$152K-2,940% | -$101K-115% | ||
| $459K— | $311K— | $50K— | $52K+127% | $0-100% | ||
| -$9.65M-49.6% | —— | —— | -$652K+89.0% | -$6.45M-52.3% | ||
| $1.63M+8.3% | —— | $2.22M+162% | $3.57M+181% | $1.5M+131% | ||
| $390K-4.9% | —— | $588K-73.6% | $759K— | $410K-33.3% | ||
| -$3.89M-83.4% | $4.71M— | -$1.41M— | $2.79M+158% | -$2.12M+53.9% | ||
| -$3.85M-2,686% | $3.35M+352% | -$1.11M-143% | $270K+108% | $149K-94.9% | ||
| -$236K— | —— | —— | —— | $0— | ||
| $1.18M-12.5% | $1.74M+24.6% | $284K-83.9% | $238K+495% | $1.34M+148% | ||
| $948K-6.0% | $1.15M+29.3% | $1.14M+19.2% | $1.1M+63.4% | $1.01M+32.6% | ||
| -$159K+84.6% | —— | -$1.08M+5.4% | -$1.16M-168% | -$1.04M-42.4% | ||
| -$2.74M-2,089% | -$771K-139% | -$3.9M-129% | $0-100% | -$125K-103% | ||
| $2.17M+155% | $1M+12.0% | $657K-35.0% | $1.58M+49.8% | $849K+49.7% | ||
| $33K+1,550% | $32K+256% | $0— | $74K-50.0% | $2K-96.4% | ||
| $6K-81.8% | $195K+2.1% | $1K-95.2% | $23K-69.7% | $33K— | ||
| -$27.08M-386% | —— | $18.92M+220% | -$16.41M— | $9.45M+264% | ||
| $0-100% | —— | —— | $4.51M+68.9% | $10.63M— | ||
| $5.07M+634% | $1.42M-49.2% | $2.09M+41,720% | $1.39M— | $690K-50.5% | ||
| $869K-42.8% | $2.94M+2,015% | $145K+3.6% | $142K+2.2% | $1.52M+992% | ||
| $21K-46.2% | $85K-38.4% | $137K-6.8% | $64K-71.4% | $39K-92.3% | ||
| $3.98M+134% | -$1.23M+66.3% | —— | -$2.6M-52.1% | -$11.55M-816% | ||
| $646K+153% | $1.41M-7.0% | $846K— | -$921K-141% | -$1.23M-172% | ||
| -$25.19M-631% | -$2.43M+96.2% | —— | -$19.83M-326% | -$3.45M-328% | ||
| -$3.75M— | $2.13M+12.0% | $0-100% | $25K-97.6% | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $1.18M-12.5% | $1.74M+24.6% | $284K-83.9% | $238K+495% | $1.34M+148% | ||
| -$389K-6.6% | -$293K+73.7% | -$252K-411% | -$223K-7,333% | -$365K-445% | ||
| -$159K+84.6% | —— | -$1.08M+5.4% | -$1.16M-168% | -$1.04M-42.4% | ||
| -$3.85M-2,686% | $3.35M+352% | -$1.11M-143% | $270K+108% | $149K-94.9% | ||
| -$47K-132% | -$761K+90.1% | $141K+117% | $144K-1.4% | $148K-50.8% | ||
| $193K-38.5% | $1.24M+361% | $132K-61.3% | $21K-83.2% | $314K-65.6% | ||
| -$1.26M+15.9% | —— | —— | -$1.62M-36.5% | -$1.49M-24.2% | ||
| $948K-6.0% | $1.15M+29.3% | $1.14M+19.2% | $1.1M+63.4% | $1.01M+32.6% | ||
| -$236K— | —— | —— | —— | $0— | ||
| $459K— | $311K— | $50K— | $52K+127% | $0-100% | ||
| $33K+1,550% | $32K+256% | $0— | $74K-50.0% | $2K-96.4% | ||
| $6K-81.8% | $195K+2.1% | $1K-95.2% | $23K-69.7% | $33K— | ||
| $239K+85.3% | $268K+106% | $171K+17.1% | $102K-21.5% | $129K-12.8% | ||
| $869K-42.8% | $2.94M+2,015% | $145K+3.6% | $142K+2.2% | $1.52M+992% | ||
| $1.31M+459% | $44K-43.6% | $45K— | —— | $234K-18.8% | ||
| -$159K+84.6% | —— | -$1.08M+5.4% | -$1.16M-168% | -$1.04M-42.4% | ||
| $3K-93.6% | $15K— | —— | —— | $47K+2.2% | ||
| $0-100% | $1.09M+1.1% | —— | $7.43M— | $599K— | ||
| -$3.75M— | $2.13M+12.0% | $0-100% | $25K-97.6% | $0— | ||
| $180K— | —— | —— | —— | $0— | ||
| -$4.9M-403% | -$1.77M-261% | -$4.56M-137% | -$1.47M-129% | -$974K-129% | ||
| -$4.9M-403% | -$1.77M-261% | -$4.56M-137% | -$1.47M-129% | -$974K-129% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cytek Biosciences, Inc. generate?
- Cytek Biosciences, Inc. (CTKB) generated -$7.4M in operating cash flow over the trailing twelve months.
- What is Cytek Biosciences, Inc.'s free cash flow?
- After $5.4M of capital expenditures, Cytek Biosciences, Inc.'s free cash flow was -$12.7M over the trailing twelve months, down 172.6% year over year.
- Where does Cytek Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
